<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:department>Pure and Applied Chemistry</gtr:department><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D09AE664-41EE-4980-B9DB-36942A07FC83"><gtr:id>D09AE664-41EE-4980-B9DB-36942A07FC83</gtr:id><gtr:firstName>Mark Christopher</gtr:firstName><gtr:surname>Bagley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D88D7B18-8C60-4526-A8D0-AFF562796653"><gtr:id>D88D7B18-8C60-4526-A8D0-AFF562796653</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Tomkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FI037229%2F1"><gtr:id>86AF25DC-094D-4E67-A4D9-1D22BCD54FDD</gtr:id><gtr:title>Alignment of Synthesis, Medicinal Chemistry and Structural Genomics to Accelerate UK Drug Discovery: Network SMS-Drug</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/I037229/1</gtr:grantReference><gtr:abstractText>This programme will establish an Academia-Users Network in Chemical Biology to initiate, establish and nurture collaborative projects for the advancement of the drug discovery process. It aims to expand the capability of UK drug discovery, with new drug targets, new tools to validate targets and new multidisciplinary partnerships to explore the platforms, tools and targets of the future.

In the post-genomic age opportunities for the development of new clinically validated targets for drug discovery and ultimately medicines are considerable. Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships.

The major obstacle to clinical validation of new drug targets and the invention of new medicines is the availability and efficient delivery of small-molecules probes in order to understand the basic biology. Provision of these probes will allow for pre-clinical validation of drug targets and reduce the duplication of efforts across the pharmaceutical industry. Failures of potential drug molecules in late stage clinical trials result in enormous cost to the companies involved, the pharmaceutical industry in general and also dashes the hopes of countless patients.

A relatively poor understanding of disease mechanisms, particularly in humans, confounds the drug discovery process and represents a pivotal area of biological research. Potent, selective and cell-permeable chemical probes are valued reagents in both fundamental and applied biological research, and they are essential for preclinical target validation in academic and industrial laboratories.

Strategic alignment of academic synthetic chemists, molecular modellers and structural biologists with industrial end users will provide a blueprint for the provision of open access chemical probes to support clinical validation and drug discovery efforts within the UK.</gtr:abstractText><gtr:potentialImpactText>This programme is a fully integrated network which will deliver the strategic alignment of academic synthetic chemists, molecular modellers and structural biologists with industrial end users to provide a blueprint for the provision of open access chemical probes to support clinical validation and drug discovery efforts within the UK. It will establish an Academia-Users Network in Chemical Biology to initiate, establish and nurture collaborative projects for the advancement of the drug discovery process. It aspires to expand the capability of UK drug discovery, with new drug targets, new tools to validate targets and new multidisciplinary partnerships to explore the platforms, tools and targets of the future.
Key to the success of this programme will be to identify funding mechanisms to deliver the resources necessary to undertake the collaborative ventures identified by the network. Working groups will be established at each interface to enable the realization of potential impact and to ensure the future success of activities initiated within this programme.
The pharmaceutical industry contributes an estimated trade balance surplus of &amp;pound;3.5 billion to the UK economy and is the world's third largest exporter of medicines. This research-driven industry is one of the UK's most dynamic industries and of key importance to the economy. Global spending on prescription drugs was in excess of $643 billion (2006) with emerging markets such as China, Russia, South Korea and Mexico experiencing a colossal 81% increase in expenditure during this period. Despite this huge economic driving force only 26 new drugs were launched worldwide in 2009.
Despite advances in technology and scientific understanding of biological systems, drug discovery is still a lengthy, expensive, difficult and inefficient process with a low rate of new therapeutic discovery. The cost of developing a new drug is estimated to be $1 billion (not including marketing expenses) which has also contributed to a lobal slowdown in drug development. In 2007 it was estimated that in the USA alone $40 billion of sales was lost by the top ten pharmaceutical companies as a result of slowdown in R&amp;amp;D innovation and the expiry of patents on major products.
The impact of drug development is clear. In order to maintain the UK at the forefront of world research it is essential that drug discovery efforts are underpinned by a scientific community that can provide the appropriate chemical tools, developed to perform basic fundamental biology to clinically validate potential drug targets. The need for innovative medicines acting via novel mechanisms of action to tackle debilitating disease states is essential for human health and well being. The provision and validation of new targets for chronic disease states of interest, including rheumatoid arthritis, metabolic disease, neurological disease, and cancer, will provide a focal point to the activities of this network.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>184149</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Joint research with University of Sussex</gtr:description><gtr:id>FC75F0F5-9CF8-4E6B-BF11-6DCD18328C28</gtr:id><gtr:piContribution>University of Strathclyde researchers worked on this project with researchers from University of Sussex</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Privileged Structures and Metallodrugs in Medicinal Chemistry 22 November 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>984020BD-D437-456F-A1FD-9E7E6E2F5FD3</gtr:id><gtr:impact>SMSdru.net committee member presented;Privileged Structures and Metallodrugs in Medicinal Chemistry&amp;quot; at Universit&amp;eacute; de Strasbourg International Symposium of Metal-Mediated Chemistry, 22/11/2013
22 novembre 2013, Salle des Th&amp;egrave;ses du Nouveau Patio, Campus Esplanade

Networking</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Network of Networks</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>403A7511-8547-4CA9-B111-D7AABBBDE74F</gtr:id><gtr:impact>Network of Networks
SMSdrug.net participated in the Chemical Biology Network of Networks meetings:
28 October 2011
02 March 2012
19 March 2012
13 June 2012
10 September 2012
30 September 2012


SMSdrug.net secured CBID support for 3 meetings as a result of contacts made.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Untargeted Kinome 27/03/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A4A40AEF-F4AC-4421-A251-95FFC1DCB4CB</gtr:id><gtr:impact>Participant : Organiser of major conference.

The Untargeted Kinome PI attended conference, organiser.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parallel Synthetic Routes to Heterocycles of Biological Importance 4th Jan 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>71F6CDD3-25E2-454E-972F-B6682EA3AD6F</gtr:id><gtr:impact>Committee member of SMSdrug.net presentation at RSC Heterocyclic and Synthesis Group, January meeting 2013, QMUL. 



98 participants from academia and industry.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ChEMBL in Allosterism</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31F9F312-39E6-4C81-92D3-7D63FEE046A6</gtr:id><gtr:impact>Member : To be assigned
Teleconference to update on Allostery Working Group Progress


Preparation for meeting on Predictive and Rational Allosteric Drug Design: 5th December 2012 in Edinburgh</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ChEMBL / SMSdrug.net tour of UK Chemistry Departments (April 2013)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6CFC89B-3E6C-4D2C-8E10-9973C297B2D0</gtr:id><gtr:impact>ChEMBL / SMSdrug.net tour of UK Chemistry Departments: 
Monday 8th April 2013 University of Edinburgh, 
Tuesday 9th April 2013 University of Strathclyde, 
Wednesday 10th April 2013 Durham University &amp;amp; Newcastle University
, Thursday 11th April 2013 University of Bradford &amp;amp; University of Sheffield, 
Friday 12th April 2013 University of Birmingham
, Monday 15th April 2013 University of Nottingham &amp;amp; University of Warwick, 
Tuesday 16th April 2013 University of Bath &amp;amp; Cardiff University, 
Wednesday 17th April 2013 University of Southampton, 
Thursday 18th April 2013 University of Sussex, 
Friday 19th April 2013 University of Oxford. ~230 total audience who fed back ideas on potential improvements to ChEMBL


Feedback was used for future updates of ChEMBL.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Opportunities in Synthetic Biology</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>ADD4BECB-9CD5-48A5-B072-7B9B5169776D</gtr:id><gtr:impact>Member : To be assigned
.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Natural Products and Their Biological Targets</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E3BC80AF-75CD-4E9D-8EC6-61834CEB6989</gtr:id><gtr:impact>SMSdrug.net and Glasgow Chemical Biology Netwrok organised a visiting lecturer to gave a seminar at the University of Strathclyde 5th March The title of the talk: Natural Products and Their Biological Targets.

Part of Glasgow Chemical Biology Network's activities.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SMSdrug.net Poster</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>66AA5C8B-7BDC-4280-9B4A-9BE125DD09B1</gtr:id><gtr:impact>Poster Presentation by SMSdrug.net at EPSRC Theme day in London on 3rd December 2013

Attendence requested by EPSRC</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Identifying and Developing Opportunities at the Chemistry Life Science Interface 4th May 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>02166DAA-F874-4E1A-A864-6AA89A0C55F5</gtr:id><gtr:impact>Participant : Organiser of special symposia : Network SMS drug meeting between 12 Chemists and Biologists to identify mechanisms to promote interaction between the disciplines.

discussion to identify mechanisms to promote interaction between the disciplines.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brighton and Sussex Cancer Working Group,  meeting 15th August 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F771FD2C-C336-4150-981B-2D8C6AB62B96</gtr:id><gtr:impact>First meeting of new Brighton and Sussex Cancer Research Network

Plans were made for a programme of events and set up of dedicated web page .</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chemistry Life Science Interface</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8C9DF5C7-BCB1-40A3-9306-C04D62DAF6DF</gtr:id><gtr:impact>SMSdrug / Biocity Scotland Research Opportunities Visit to Newhouse 26/11/12</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Understanding the Rhythm of Pulmonary Inflammation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C9C6A86-1CE2-48CA-882B-4388801FE092</gtr:id><gtr:impact>PI's group member Presented talk and poster titled: Understanding the Rhythm of Pulmonary Inflammation. 
Drug Discovery Chemistry, San Diego, CA, USA. 23rd &amp;amp; 24th April 2014



Poster was distinguished and selected by the conference organisers for a talk delivered in the Anti-inflammatories: Small Molecules Approaches track.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allosteric Drug Design 30th April 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F047FF48-3D51-4AB0-8F37-23DB6591F526</gtr:id><gtr:impact>Allosteric Drug Design Seminar with presentations from speakers from University of Geneva, an SME and EBI to audience of ~45 postgraduates and acadmics. Followed by a round table with 10 participants who discussed potential funding applications.

This engagement led to an application for a Marie Curie fellowship in Sept 2014 by one of the participants.
The event was part of Engage With Strathclyde week of events to encourage external enagement with the University of Strathclyde.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Innovative targets for circadian drug discovery REV-ERBa and RORa</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C7E6D566-C1DD-48EA-8B97-A4813FE00A53</gtr:id><gtr:impact>A member of PIs group Presented talk titled: Innovative targets for circadian drug discovery REV-ERBa and RORa.
European Medicines Research Training Network (EMTRAIN). Drug discovery: development workshop for public-private partnership PhDs and PostDocs held at GSK, Stevenage, UK. 14-17 April 2014


Networking activity</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RICAS - SMSdrug 16th August 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>02D9791E-CC85-42DD-BA8A-D8E2AD1F75BB</gtr:id><gtr:impact>Meeting between SMSdrug.net and RICAS members to establish areas of common interest.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Second Cancer Biology/Chemical Biology Meeting 28th October 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2AE81261-0B49-4104-A8C2-7E6B02888CC3</gtr:id><gtr:impact>43 Researchers and KE professionals met to present, discuss and share opportunities for collaborative interactions in cancer at the chemical biology interface.

Glasgow CRUK Development fund of &amp;pound;25,000 has been ring-fenced for this year to collaborative projects between Chemists' and Biologists' working in Cancer Therapy.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.smsdrug.net/showNews.php?ID=133</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>From Natural Product Synthesis to Chemical Intervention in Aging</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8AF81DAC-7208-4DFB-A111-B5DBB253031B</gtr:id><gtr:impact>Presentation by CoI , Presentation at Universiteit Gent, Belgium on 30th May 2013 and Katholieke Universiteit Leuven, Belgium on 31st May 2013. Around 20 academics in audience for each presentation.



20 participants from academia at each presentation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Privileged Druglike Libraries for Biological Evaluation and An Introduction to SMSdrug.net</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0F92559-EA72-43AE-9841-2A1A002A5AEE</gtr:id><gtr:impact>Society for General Microbiology at Sussex in Sept (2-4) 2013.
http://www.sgm.ac.uk/en/media_centre/society-news.cfm/sgm-autumn-conference-2-4-sept-2013-university-of-sussex 
Presentation given to 98 participants.
&amp;quot;Privileged Druglike Libraries for Biological Evaluation and An Introduction to SMSdrug.net&amp;quot; by CoI and committeee member (University of Sussex) 



A short presentation on the role of SMSdrug.net, a MRC-BBSRC-EPSRC joint initiative for bringing together chemists and biologists to collaborate on drug discovery, was given . This was followed by a short account on the types of molecules (libraries) made in the Spencer laboratory, of potential use to microbiologists for testing and as chemical tools for biological research. The libraries consist of a number of privileged scaffolds including benzodiazepines, oxazoles, pyrimidines and benzotriazepines.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>What's the use of Chemistry? 8th Feb 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5748DBFF-F16B-4271-ADEA-DD1BB5940A24</gtr:id><gtr:impact>Presentation by CoI at Sir George-Monoux 6th Form College. 40 participants from secondary education.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dial-a-Moleclule annual meeting 02/07/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C9D01721-04A2-4CE3-9FED-D8BC5001DEAC</gtr:id><gtr:impact>Participant : Participation in workshop, seminar, course.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Chemical Biology Network 11th June 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3A19941A-B3A0-4389-A482-BA30C38A043F</gtr:id><gtr:impact>Glasgow Chemical Biology Network - Seminar with speakers from University of Strathclyde SIPBS followed by discussion.

Meeting took place by request from Chemists from University of Glasgow</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Privileged Structures and Metallodrugs in Medicinal Chemistry 28th June 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F41C1E59-C9D5-46E3-915A-532BC02123AD</gtr:id><gtr:impact>Presentation at Departemento de Quimica, Faculade de Ciencias e Tecnologia,Univeridade Nova de Lisboa, 2829-516 Caparia, Portugal

20 participants.

SMSdrug.net committee member (University of Sussex) &amp;quot;Privileged Structures and Metallodrugs in Medicinal Chemistry&amp;quot; presented at **Departamento de Quimica, Faculdade de Ci&amp;ecirc;ncias e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal 20 participants.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Therapeutic strategies targeting the spliceosome 2nd February 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DC21C6E-CE0E-46D4-89BF-355736934854</gtr:id><gtr:impact>PI's meeting (29) and session 5 of 3rd UK RNA Splicing Conference at Rydal Hall (85 registered) supported by SMSdrug.net. Discussion around potential for an RNA Splicing network for UK.

Follow Up meeting planned for Sept 2013 at RSC Chemistry Centre, London</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radiopharmaceuticals working group meeting 13 Aug 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6EC46D70-AD29-40DF-9CC7-8F0553F3B7E2</gtr:id><gtr:impact>Radiopharmaceuticals working group meeting 13 Aug 2014

Discussed workplans and future funding applications</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RNA Splicing Group 3 Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1A21F355-940A-4A6F-AC6C-6FE744792C39</gtr:id><gtr:impact>SMSdrug.net organised a meeting for a group of researchers to discuss making applications to the SULSA Assay Development Fund

2 Applications were made as a result of this meeting and accepted</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NOVEL SYNTHETIC LIGANDS TO PROBE THE ROLE OF REV-ERBa IN INFLAMMATORY DISEASES</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65318196-08B7-4E3D-AE50-022893F640F3</gtr:id><gtr:impact>EFMC-ISMC 2014
XXIII International Symposium on Medicinal Chemistry
Lisbon, Portugal - September 7-11, 2014
Poster Presentation: NOVEL SYNTHETIC LIGANDS TO PROBE THE ROLE OF REV-ERBa IN INFLAMMATORY DISEASES


Presentation of Circadian Research to academic audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Matchmaking Ethical Medium Throughput Screening with Chemistry 12th June 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99C7D559-5971-451F-9579-DB9EAF9C656C</gtr:id><gtr:impact>SMSdrug.net and CBID Meeting to explore potential collaborations at RSC Chemistry Centre

14 Participants</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mechanical Loading and Disease: Model systems to investigate the interactions between genotypes associated with osteoporosis, osteoarthritis and sarcopenia (11th Jan 2013)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>862E6F02-DC2C-4CF6-B701-78CC8098A00D</gtr:id><gtr:impact>Consortium meeting, Hilton Hotel, Heathrow. 17 participants from EU academia and industry

Collaboration/Partnership - Consortium Meeting, Hilton Hotel, Heathrow.
Mechanical Loading and Disease: Model systems to investigate the interactions between genotypes associated with osteoporosis, osteoarthritis and sarcopaenia
17 participants from EU academia and industries. Contributor: CoI</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Using Synthetic Biology to Dial-a-Molecule (18 February 2013)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7651D83C-AEDD-4B1D-8110-0DD82B2E6844</gtr:id><gtr:impact>Dial-a-molecule, SMSdrug.net, GSK supported meeting
PI Chaired meeting

PI Chair chaired meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allosterism in Scotland 12th April 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6BD9793F-6ACB-4334-9730-F3DFE8F9E66A</gtr:id><gtr:impact>Participant : Participation in workshop, seminar, course (8 participants)

Organiser : Participation in conference : Developing a UK allosteric network - University of Edinburgh.

Meeting between 8 Participants from University of Edinburgh, University of Strathclyde and Koc University Turkey</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Identifying and developing opportunities at the Chemistry Life Science interface 15/06/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>269661EC-F7A2-4747-AB36-C3BB7BEAB772</gtr:id><gtr:impact>Member : Participation in workshop/networks with non-academic organisation.

Meeting with BioQuarter.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SMSdrug interface with cancer research 10/04/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5142FBF6-05E7-4DF9-B6EF-03C35DB5A5A7</gtr:id><gtr:impact>Member : Participation in workshop/networks with non-academic organisation.

SMSdrug.net Interface with Cancer Research
PI participation with workshop.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Predictive and Rational Allosteric Site Identification 29th June 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6D08A9C-167E-457D-812B-E84FF4E765AD</gtr:id><gtr:impact>Working Group Meeting at RSC Chemistry Centre, supported by CBID and SMSdrug.net. 
The group of 12, identified actions to help ascertain whether a suitable allosteric target could be identified.

The results of these actions were collated and circulated to the group. Another meeting planned as a follow up and discussions continued at that meeting.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Centre for Rational Allosteric Drug Design</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F97591F5-39A8-48AB-943F-23FE810EDB69</gtr:id><gtr:impact>CRADD Monthly meetings



CRADD: Centre for rational allosteric drug discovery
Through a combined research effort of molecular modelling, informatics, synthesis, medicinal chemistry and biological evaluation across three Departments within the University of Strathclyde together with structural support provided by the SGC Oxford. 
This research grouping aims to:
? Deliver the first in silico designed allosteric binding inhibitor for a kinase
? Establish SID-MD analysis as a major tool for structure-based allosteric drug discovery through crystallographic validation
? Provide a bespoke method for the identification and validation of allosteric binding sites within proteins

SMSdrug Administrator organised a series of meetings for the CRADD group.

Meeting Dates: 
11th October 2012
06 November 2012
15 January 2013
12 March 2013
17 April 2013 
30 August 2013
03 October 2013
26 November 2013
21st January 2014
20 February 2014
23 July 2014
26 September 2014


One member of this group has organised the Allosteric Drug Design Event that took place on 30th April 2014 and made an application for Marie Curie Fellowship during 2014. Another member has plans for a Placement with a Spanish group due to take place in 2015. Research efforts are ongoing so full impact unknown at this stage.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Chemical Biology Network December 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>37069AE9-ADA2-4F93-A326-6C21BF695274</gtr:id><gtr:impact>Presentations at University of Glasgow, followed by discussion

Plans for future interactions made by some of the group members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rational and Predictive Allosteric Design (5th Dec 2012)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DC361639-766A-4743-9AB8-4342373B9232</gtr:id><gtr:impact>Organised Meeting. Program of activities agreed with a view to trying to achieve PoC which should allow funding application or collaborative venture to be initiated in future. 
Established interest in working towards achieving funding for new project.

Established group working towards achieving funding for new project.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DDP  and RSC Meeting Dec 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E3DD9EFE-D1B5-4833-900C-C67ED8D54085</gtr:id><gtr:impact>Meeting between Drug Discovery Portal researchers and RSC ChemSpider team.

Plans for future collaboration</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Identifying and developing opportunities at the Chemistry Life Science interface 10/05/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0B6129B3-2C75-4EA4-828B-34D31A81A99B</gtr:id><gtr:impact>Meeting with University of Dundee.


Dundee library added to DDP</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beyond the paper resume and how to develop an online profile as a scientist</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>85E87476-0890-42FA-89C3-8EE344D63AE9</gtr:id><gtr:impact>Beyond the paper resume and how to develop an online profile as a scientist
Presented by visitor from Royal Society of Chemistry at University of Strathclyde. Audience of 25 postgraduates.

Networking between RSC and University of Strathclyde</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Sussex, School of Life Sciences Visiting Lecturers Programme</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>20531B86-72AF-4A74-92C5-9BB9E8E88E8C</gtr:id><gtr:impact>University of Sussex, School of Life Sciences Visiting Lecturers Programme
Organised by CoI of SMSdrug.net
29 October 2012: Small molecule screen for altered sleep in zebrafish
31 October 2012: Electronic, Molecular and Materials Systematics: The 'Stamp Collecting' Approach To Answering Chemical Questions
07 November 2012: Equisetin, Reutericyclin and Streptolodygin: Natural Product Lead Structures for Novel Antibiotics
21st November 2012: Adventures in Non-Covalent Chemistry: From Self Assembly to Protein-Surface Recognition
05 December 2012: Synthesis and Evaluation of New Cancer Medicines
13 February 2013: Alzheimer's Disease; from Bench to Bedside
20 February 2013: Chemistry Illuminating Biology: the Design and Synthesis of Chemical probes for Biological Systems
06 March 2013: Highly Reactive Nitrogen Heterocycles - Synthesis and Properties
13 March 2013: Chemistry and biology of englerin A
15 May 2013: Microscopy for Synthetic Chemists and Dual-Metal Catalysis with Gold
29 May 2013: Ion Binding and Asymmetric Catalysis
22 May 2013: Minimal artificial tissues from communicating droplet networks 
11 July 2013: Nature's medicine chest: opportunities for drug discovery


Networking activity</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Chemical Biology Network - Cancer Meeting</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5F815A66-FF42-4D72-8C6C-994D1501276A</gtr:id><gtr:impact>A Cancer Clinician visited Glasgow Chemical Biology Network and gave an overview on cancer research taking place in Glasgow followed by discussion.

Plans made to hold a future sandpit type event for researchers in the city of Glasgow</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Identifying and developing opportunities at the Chemistry Life Science interface 25/05/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>69639358-00D1-499F-9172-FBF5932D13FA</gtr:id><gtr:impact>Member : Participation in workshop/networks with non-academic organisation.

Meeting with BioCity Scotland at Newhouse.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Therapeutic strategies targeting the spliceosome 12th December 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>90DAA43C-722C-4FB7-B46D-52EF6EE522A8</gtr:id><gtr:impact>SMSdrug.net and RSC CBID Meeting at RSC Chemistry Centre: 18 participants

Follow Up meeting planned for Feb 2013</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chemical Probes for REV-ERBalpha</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8289294D-6C3B-4054-A8A5-912BE3813C8F</gtr:id><gtr:impact>Poster presentation at RICT 2014: Title of Meeting: Rencontres Internationales de Chemie Th&amp;eacute;rapeutique 2014 (RICT 2014): Interfacing Chemical Biology and Drug Discovery
Title of poster: Chemical Probes for REV-ERBalpha
Brief description of poster content: 
The circadian clock is responsible for the day and night cycle of many of the planet's organisms. The clock is responsible for many important biological pathways such as sleep cycles, metabolism and inflammation. It has been reported that REV-ERB? is at the centre of the circadian clock and is part of the mechanism that controls the inflammatory response and the metabolic state of the organism. Therefore further studies into the function and responses of REV-ERB? will allow a greater insight into the circadian rhythm with the ultimate goal of identifying a receptor as a therapeutic target for a broad range of diseases, including inflammation.

Poster won RICT Poster Prize 2014
Details of what was won: Free attendance to RICT2015 in Avignon with 2 nights accommodation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mechanisms, regulation and uses of OTU deubiquitinases</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>75919678-C948-44D7-B035-564183E8A175</gtr:id><gtr:impact>SMSdrug.net and Glasgow Chemical Biology Network organised visiting lecturer who presented: Mechanisms, Regulation and Uses of OTU Deubiquitinases on Wednesday 19th March, Department of Pure and Applied Chemistry, University of Strathclyde

Part of Glasgow Chemical Biology Network activities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Drug Discovery 15/10/13</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9E3FD13D-5857-441C-A083-9654276C6782</gtr:id><gtr:impact>51 participants attended a seminar organised by SMSdrug.net to celebrate the launch of the new drug discovery portal website.


This event led to further meetings between University of Strathclyde and BioAscent; University of Strathclyde and RSC ChemSpider team.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clyde CHEM</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>55A97929-E7E3-4E38-B45A-F32526D4EB3B</gtr:id><gtr:impact>Chair : To be assigned
.

Clyde CHEM meeting between University of Strathclyde and University of Glasgow Chemists
PI chaired meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RNA Splicing Group 1 Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BECCAAC9-7548-4C14-B97C-7215EC8A33F6</gtr:id><gtr:impact>A group of researchers met and agreed to write and submit an sLola BBSRC application on RNA Splicing research.

Funding application made as a result of this meeting, but was not successful. A further meeting planned for late 2014 or 2015 to discuss the next steps.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Opportunities for Chemists in Stem Cell Research</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>0935B029-F988-4AC3-9195-D3939F906149</gtr:id><gtr:impact>Member : To be assigned
.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Developing Opportunities at the Chemistry-Life Science Interface</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>066C0473-8772-4E62-B3E4-8A6220595B64</gtr:id><gtr:impact>Contributor : To be assigned
.

23 - 28 April 2012 Developing Opportunities at the Chemistry Life Science Interface 
PI visit to India
Potential Collaborations / Networking
Mithibi College, Vile Parle, Mumbai
Medical Research Centre - Katsurba Health Society
Ruia College, Mutanga, Mumbai
Institute of Chemical Technology, Matunga, Mumbai
V.G. Vaze College, Miland, Mumbai
Sir Parashurambhau College, Pune
Emcure Pharmaceuticals, Pune
University of Naigpur Institute of Science and Forensic Science
University of Naigpur, Chemistry Department
SM Pandav College of Engineering, Naigpur</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Synthetic Chemistry for the Life Sciences 11/01/2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37C7494C-F606-4762-B13D-77B62BCBD0FD</gtr:id><gtr:impact>Participant : Participation in workshop, seminar, course : Network event to develop Chemistry at the Life Sciecne interface.

Synthetic Chemistry for the Life Sciences. Participant : Participation in workshop, seminar, course : Network event to develop Chemistry at the Life Science interface University of Liverpool</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Therapeutic Strategies Targeting the Spliceosome Sept 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C2DC8860-E9EC-42CB-A29F-6E5BB3C9B698</gtr:id><gtr:impact>SMSdrug.net organised a meeting at the RSC for a group of 19 researchers in RNA Splicing

Researchers in the UK RNA splicing community agreed to meet again during 2014 with the purpose of making funding applications. Further meetings held during Q1 2014</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Relevant Challenges in Chemical Biology 27th Sept 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23EC0622-0514-47D3-8564-45BDF7931C78</gtr:id><gtr:impact>Meeting of Industry Panel Members and SMSdrug.net Committee.

Informed future direction for SMSdrug.net</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chemistry Life Science interface meeting (19th April 2012)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>30E86F06-21C9-41F3-94C3-4885D3B913A9</gtr:id><gtr:impact>Meeting between SMSdrug.net members and BioCity Scotland.

Secured follow Up meeting on 25th May 2012 at Newhouse</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cooking your results with microwaves</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F0195F0F-FD43-4345-BCCE-FF0861C85F0A</gtr:id><gtr:impact>Seminar: Cooking your results with microwaves, presentation by CoI at Teacher's CPD conference, University of Sussex
32 delegates

Teacher's CPD conference, University of Sussex
32 delegates</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Drug discovery: leveraging academic impact through novel fragments 05/02/2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D43FD036-ED0D-4A99-9E9C-514C58BE12E5</gtr:id><gtr:impact>Organiser: PI &amp;amp; Participant: SMSdrug.net committee member

Dial-a-molecule, 3D Frag, The Royal Society, University of Huddersfield, 3M Buckley Innovation Centre and SMSdrug.net - Huddersfield 
Numbers max: 40, A committee member attended on behalf of SMSdrug.net, PI wasan organiser of this meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imaging and Pathway Profiling: Advancing cancer drug discovery towards improved clinical efficacy 16th Jan 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A147131D-0CE5-49A3-AFE8-1703BF875A4E</gtr:id><gtr:impact>Presentation by visitor from University of Edinburgh at University of Strathclyde, followed by discussions with academics.

40 attended presentation followed by networking and discussions with academics</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ChEMBL Tour EU 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1F27B197-B234-4A25-B7C2-56FEFDBB3CF4</gtr:id><gtr:impact>ChEMBL Tour EU 2014
Following the success of the 2013 ChEMBL Tour SMSdrug.net supported last year, the ChEMBL curator was supported to fundertake a 2014 ChEMBL tour. The EU 2014 tour visited mainland Europe and some dates will included a presentation on Allosteric Modulators which refer to this recent publication: van Westen GJP, Gaulton A, Overington JP (2014) Chemical, Target, and Bioactive Properties of Allosteric Modulation. PLoS Comput Biol 10(4): e1003559. doi:10.1371/journal.pcbi.1003559.
Dates as follows:
19th of May - Maastricht University- Host Egon Willighagen / ChEMBL + Allosteric modulators
20th of May - Maastricht University- Host Jos Kleinjans / ChEMBL + Advanced ChEMBL
20th of May - KU Leuven - Host Pieter Annaert / ChEMBL
22nd of May - Universiteit Antwerpen - Host Koen Augusteyns / ChEMBL
26th of May - VU University Amsterdam - Host Rob Leurs &amp;amp; Universiteit van Amsterdam - Host Willem Stiekema / ChEMBL + Allosteric modulators
28th of May - University of Groningen - Host Alexander Domling / ChEMBL + Advanced ChEMBL
6th of June - Utrecht University - Host Roland Pieters / ChEMBL
6th of June - Universiteit Leiden - Host Ad IJzerman / ChEMBL
17th of June - Erasmus Medical Centre, Rotterdam - Host Roland Kanaar / ChEMBL
18th of June - Radboud University Nijmegen - Host Tina Ritschel / ChEMBL + Allosteric modulators



Feedback via ChEMBL-og has resulted in plans for a USA leg of the tour.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Glasgow Centre and SMS Drug Network Chemical Biology-Cancer Biology Meeting 14th May 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>82D55CA1-FDB1-404F-B289-33956E0E2762</gtr:id><gtr:impact>SMSdrug.net and CRUK Beatson organised this meeting. Around 70 participants attended this event which was a series of 5 minute talks by 21 participants from across the city of Glasgow: CRUK Beatson, University of Glasgow, University of Strathclyde and NHS. The aim was to stimulate new collaborations.

A follow up meeting focused towards supporting researchers to apply for CRUK Glasgow Centre development funding planned for October 2014</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>92750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Engineering and Physical Sciences Research Council EPSRC</gtr:department><gtr:description>Alpha-Helical Mimetics</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:fundingRef>EP/M507568/1</gtr:fundingRef><gtr:id>CB3DA042-685E-48F8-87A3-AFD48B87E9EC</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>51999</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NPC-C: Adding a Chemistry Element to Niemann-Pick C Research</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Niemann-Pick Research Foundation</gtr:fundingOrg><gtr:id>FB34CDB2-785A-4AED-BC38-BC8194F8B880</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK. Drug Discovery Project award</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>9E0C3816-A3C2-4AAA-9409-0181FF5617E4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A new strategy to approach orphan disease: disrupting dominant negative activity in nuclear receptors</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Royal Society of Chemistry</gtr:fundingOrg><gtr:id>F69BB22F-D8EF-4966-A7D4-C5AE54731ECB</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rescuing Thermally Unstable p53 Mutants with Small Molecules; New Targeted Cancer Therapies</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef> 14-1002</gtr:fundingRef><gtr:id>7C702CAB-DF44-4412-8B14-E60A8280CA51</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neuroprotective compounds acting as antagonists at A2a receptors</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>DABDAD5C-31F0-4BDD-94C2-99C16A0D5714</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rescuing p53 Mutants in Cancer</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef>14-1002</gtr:fundingRef><gtr:id>9A4D75A2-EDA2-4BCA-81D6-25DE1C9A079D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49073</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Identification of pre-clinical SK1 inhibitors for the treatment of Pulmonary Hypertension</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>2677524A-94C0-4D84-B2EA-CCACB56C62BD</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>Thailand, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Synthesis of Bioinorganic Probes</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Government of Thailand</gtr:fundingOrg><gtr:id>35C6239C-55CA-433B-BB0F-FF29D42F4A6A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200001</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>First in class selective IKKalpha Inhibitors for Evaluation in Pancreatic Cancer</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>D178273F-734F-41E9-B920-0C997F41FC78</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460842</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fatty Acid Specificity in the DHHC Family of S-Acyltransferases: From Mechanisms to Functional Outcomes</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>81548EF5-3645-4417-8016-8932E979F43A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>171652</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Small Molecules to Target Stem Cells and the Niche to Improve Endogenous Repair</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8528F7E8-8940-48CF-A68E-3613ADCB5623</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4590070</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre for Regenerative Medicine (CRM): A hub for Engineering and exploiting the stem cell niche (April 2013)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K026666/1</gtr:fundingRef><gtr:id>587C70F5-8DC7-4F46-BDA0-AAAE53216A96</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IKKalpha Inhibitors for the Treatment of Castrate Resistant Prostate Cancer (CRPC) and Pancreatic Cancer</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>34853769-7B27-4755-B8B2-F81A5BD5AB75</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Small molecule regulators of the p53 interacting kinases</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>B11314D1-B85E-4CFF-A383-1E834FE05BD2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>375000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DHHC drug discovery programme</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>ONO Pharmaceuticals</gtr:fundingOrg><gtr:id>C4AAE2E5-4CE0-410B-9E3E-7C4DBA21A7E1</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>567126</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fatty Acid Specificity in the DHHC Family of S-Acyltransferases: From Mechanisms to Functional Outcomes</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F1E6C5D2-ACF2-4F31-B654-A917ED382D6E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Synthesis and Evaluation of Copper probes for NPC</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Niemann-Pick Research Foundation</gtr:fundingOrg><gtr:id>4B20F433-F399-404B-987C-E60939F91199</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>A series of working groups have been established and their efforts are focussed on defining projects and identifying means to appropriately resource these endeavours. To date, three working groups have been successful in securing major grant income. This method of promoting collaborative research will be continued to increase the reach of this Network.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>771CE308-5E6F-4717-919B-1F91EC8EB7B8</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:sector>Chemicals,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Key metrics from the grant include:

1. Over 1000 people from 78 organisations have engaged with SMSdrug.net.
2. Involvement from 44 universities, 19 companies, 15 other networks, 9 funding bodies.
3. Further Funding of over &amp;pound;5M from core members of Network.
4. 5 studentships and 3 major grants secured.
5. Members have attended events at 45 different venues.
6. ChEMBL tour visited 14 universities.
7. 196 contacts from 48 organisations have attended 16 major events.
8. 10 projects, 18 publications, and over 40 presentations on the Network from committee.
9. International involvement of the Network with Europe, North America, South America and Asia.
10. SMSdrug.net promoted at 12 Indian institutions during 2012 visit.</gtr:description><gtr:exploitationPathways>The extensive research outputs from the Network will be of use to those working in the area.

Working groups developed will continue beyond the duration of the grant.

New funding secured through the Network will allow for further research.</gtr:exploitationPathways><gtr:id>6E798A71-8AA3-496E-A7E8-142156557E14</gtr:id><gtr:sectors><gtr:sector>Chemicals,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.smsdrug.net</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Response to EPSRC as consultation exercise for new Centres of Doctoral Training (Nov 2012)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9CDEA91C-AB7C-4666-B11E-F722151A7130</gtr:id><gtr:impact>Training/educational developments (including courses and course material)
Following the identification of priority areas from the consultation, two new CDT's were established: EPSRC Centre for Doctoral Training in Physical Sciences Innovation in Chemical Biology for Bioindustry and Healthcare (EP/L015498/1) and EPSRC Centre for Doctoral Training in Advanced Therapeutics &amp;amp; Nanomedicines (EP/L01646X/1)</gtr:impact><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDBFDEB1-46CD-4F71-9518-DAC0D4E814A5"><gtr:id>CDBFDEB1-46CD-4F71-9518-DAC0D4E814A5</gtr:id><gtr:title>Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa7a95269b976b9328e0187276784e59"><gtr:id>aa7a95269b976b9328e0187276784e59</gtr:id><gtr:otherNames>Longo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7EACBB88-F965-4868-AAA0-F789F33C305E"><gtr:id>7EACBB88-F965-4868-AAA0-F789F33C305E</gtr:id><gtr:title>Identification and development of the 1,4-benzodiazepin-2-one and quinazoline-2,4-dione scaffolds as submicromolar inhibitors of HAT.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/efe625e3afc3f3a86744c758950f2a4b"><gtr:id>efe625e3afc3f3a86744c758950f2a4b</gtr:id><gtr:otherNames>Clark RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE17B2CC-2DB5-493E-A253-3D9DB3048B49"><gtr:id>CE17B2CC-2DB5-493E-A253-3D9DB3048B49</gtr:id><gtr:title>Rationalising sequence selection by ligand assemblies in the DNA minor groove: the case for thiazotropsin A</gtr:title><gtr:parentPublicationTitle>Chem. Sci.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/84617686f3f1810c22fd316eaf8b3d2d"><gtr:id>84617686f3f1810c22fd316eaf8b3d2d</gtr:id><gtr:otherNames>Alniss H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/136D5EF3-1CED-4E82-B2F4-93AFE6B8CB5B"><gtr:id>136D5EF3-1CED-4E82-B2F4-93AFE6B8CB5B</gtr:id><gtr:title>UniChem: extension of InChI-based compound mapping to salt, connectivity and stereochemistry layers.</gtr:title><gtr:parentPublicationTitle>Journal of cheminformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/590bf6865bfab157d61e6d2761727937"><gtr:id>590bf6865bfab157d61e6d2761727937</gtr:id><gtr:otherNames>Chambers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2946</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C036DF60-041B-4A55-956C-B02F539916B9"><gtr:id>C036DF60-041B-4A55-956C-B02F539916B9</gtr:id><gtr:title>Small molecule induced reactivation of mutant p53 in cancer cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42f7c7c6107a6cd7198876022cb295cf"><gtr:id>42f7c7c6107a6cd7198876022cb295cf</gtr:id><gtr:otherNames>Liu X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B50558F-3C6B-48AD-8286-B0225C357854"><gtr:id>0B50558F-3C6B-48AD-8286-B0225C357854</gtr:id><gtr:title>Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bbff28f436be792efff9e246051f13e3"><gtr:id>bbff28f436be792efff9e246051f13e3</gtr:id><gtr:otherNames>Baek DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41722755-750A-4E2F-A249-14CFF13E5D40"><gtr:id>41722755-750A-4E2F-A249-14CFF13E5D40</gtr:id><gtr:title>Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d72ab0dcb9e827da71c45603704751d"><gtr:id>0d72ab0dcb9e827da71c45603704751d</gtr:id><gtr:otherNames>Good JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31EEE1B5-76A1-4DE5-936A-D410E5CB73BB"><gtr:id>31EEE1B5-76A1-4DE5-936A-D410E5CB73BB</gtr:id><gtr:title>Amide isosteres in structure-activity studies of antibacterial minor groove binders.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1aceeda6daebd5e97ef41f505440696e"><gtr:id>1aceeda6daebd5e97ef41f505440696e</gtr:id><gtr:otherNames>Khalaf AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C18CBCF-E01D-408B-B8BF-77121F6AFDF9"><gtr:id>2C18CBCF-E01D-408B-B8BF-77121F6AFDF9</gtr:id><gtr:title>A document classifier for medicinal chemistry publications trained on the ChEMBL corpus.</gtr:title><gtr:parentPublicationTitle>Journal of cheminformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c60269f5bc6368fbc412f8edba1e0952"><gtr:id>c60269f5bc6368fbc412f8edba1e0952</gtr:id><gtr:otherNames>Papadatos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2946</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C91FC255-0BF8-43D9-92E5-785D59EAAD6E"><gtr:id>C91FC255-0BF8-43D9-92E5-785D59EAAD6E</gtr:id><gtr:title>Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ae502446aa779dc7da7485176b99fb11"><gtr:id>ae502446aa779dc7da7485176b99fb11</gtr:id><gtr:otherNames>Wang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D32C93F1-17DF-4423-ADDA-29E301DBA200"><gtr:id>D32C93F1-17DF-4423-ADDA-29E301DBA200</gtr:id><gtr:title>Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ffe47534b13f851791f2c56902b9ee09"><gtr:id>ffe47534b13f851791f2c56902b9ee09</gtr:id><gtr:otherNames>Theodoulou NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E11F8FF-4245-42BD-B95F-018B7942B6BA"><gtr:id>4E11F8FF-4245-42BD-B95F-018B7942B6BA</gtr:id><gtr:title>Carbon dots (C-dots) from cow manure with impressive subcellular selectivity tuned by simple chemical modification.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64b868479b80e3cef3745114a590d71d"><gtr:id>64b868479b80e3cef3745114a590d71d</gtr:id><gtr:otherNames>D'Angelis do E S Barbosa C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1F30655-868C-4F10-BDCF-A98B2FA09519"><gtr:id>D1F30655-868C-4F10-BDCF-A98B2FA09519</gtr:id><gtr:title>The ChEMBL bioactivity database: an update.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/511338fedf643fc4dd22b85d6ed612c1"><gtr:id>511338fedf643fc4dd22b85d6ed612c1</gtr:id><gtr:otherNames>Bento AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A0926DA-566C-4981-B590-E3C7F1F23FA3"><gtr:id>7A0926DA-566C-4981-B590-E3C7F1F23FA3</gtr:id><gtr:title>Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.</gtr:title><gtr:parentPublicationTitle>Cell chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f51f97ab5cbecafed932b0d33893219c"><gtr:id>f51f97ab5cbecafed932b0d33893219c</gtr:id><gtr:otherNames>Forster M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31E43A22-F71A-4F6D-AF2E-61B8FD60D568"><gtr:id>31E43A22-F71A-4F6D-AF2E-61B8FD60D568</gtr:id><gtr:title>Multifunctional 8-hydroxyquinoline-appended cyclodextrins as new inhibitors of metal-induced protein aggregation.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7197caeee5fa8a8448f510c5320827f0"><gtr:id>7197caeee5fa8a8448f510c5320827f0</gtr:id><gtr:otherNames>Oliveri V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B943930B-C251-4EA2-BB81-5CC10E470BD3"><gtr:id>B943930B-C251-4EA2-BB81-5CC10E470BD3</gtr:id><gtr:title>Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e6b9ba513fae611aac0e8b8872a0efa"><gtr:id>8e6b9ba513fae611aac0e8b8872a0efa</gtr:id><gtr:otherNames>Abualhasan MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E188D8FF-174B-4237-A13B-677754F2C247"><gtr:id>E188D8FF-174B-4237-A13B-677754F2C247</gtr:id><gtr:title>Understanding ageing: biological and social perspectives</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73c7e6221f34b9e351904223a29a1558"><gtr:id>73c7e6221f34b9e351904223a29a1558</gtr:id><gtr:otherNames>Cox, L. S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-1-44731-467-7</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E30BC2BB-7AA3-4285-93DE-9E32672788B6"><gtr:id>E30BC2BB-7AA3-4285-93DE-9E32672788B6</gtr:id><gtr:title>MyChEMBL: A Virtual Platform for Distributing Cheminformatics Tools and Open Data</gtr:title><gtr:parentPublicationTitle>Challenges</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/18859fae61e0bc2d32267048f675108f"><gtr:id>18859fae61e0bc2d32267048f675108f</gtr:id><gtr:otherNames>Davies M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBA1BF0A-3A57-4630-BDFB-B934A97278CD"><gtr:id>FBA1BF0A-3A57-4630-BDFB-B934A97278CD</gtr:id><gtr:title>Chemical, target, and bioactive properties of allosteric modulation.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0905c93ea1680ac62798181689f63efd"><gtr:id>0905c93ea1680ac62798181689f63efd</gtr:id><gtr:otherNames>van Westen GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6677BE0-76E5-4BFD-91C2-CD126F176871"><gtr:id>C6677BE0-76E5-4BFD-91C2-CD126F176871</gtr:id><gtr:title>Microwave-Assisted Bohlmann-Rahtz Synthesis of Highly Substituted 2-Aminonicotinates</gtr:title><gtr:parentPublicationTitle>Synlett</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14e8090fe82ea95cf1df6bf07d2bba1a"><gtr:id>14e8090fe82ea95cf1df6bf07d2bba1a</gtr:id><gtr:otherNames>Bagley M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56F4E34A-99D7-4C57-A290-5D7F14752C7D"><gtr:id>56F4E34A-99D7-4C57-A290-5D7F14752C7D</gtr:id><gtr:title>Global analysis of small molecule binding to related protein targets.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1671d1f3bf2072362298426d26347cc"><gtr:id>f1671d1f3bf2072362298426d26347cc</gtr:id><gtr:otherNames>Kruger FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD12E946-CFAE-4AFA-9EB3-CF443670A799"><gtr:id>FD12E946-CFAE-4AFA-9EB3-CF443670A799</gtr:id><gtr:title>The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8AE2DD1-AE82-455E-A4EA-6EEF44543295"><gtr:id>C8AE2DD1-AE82-455E-A4EA-6EEF44543295</gtr:id><gtr:title>Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db2c78f189625b6fe7b6288400c50463"><gtr:id>db2c78f189625b6fe7b6288400c50463</gtr:id><gtr:otherNames>Batson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2DFFFC46-4EEE-4BFF-9998-B7FBB65AAD38"><gtr:id>2DFFFC46-4EEE-4BFF-9998-B7FBB65AAD38</gtr:id><gtr:title>Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3976fc9c2f98cdcb893b459cd2e0e9a8"><gtr:id>3976fc9c2f98cdcb893b459cd2e0e9a8</gtr:id><gtr:otherNames>Dizdarevic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61A430CE-BFD2-443C-9B31-ADD9B05C748A"><gtr:id>61A430CE-BFD2-443C-9B31-ADD9B05C748A</gtr:id><gtr:title>Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e95164a0fc3eaff8ebabf7747f957680"><gtr:id>e95164a0fc3eaff8ebabf7747f957680</gtr:id><gtr:otherNames>Petch D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA093365-FE1D-439D-999A-4EEF662BA1D4"><gtr:id>DA093365-FE1D-439D-999A-4EEF662BA1D4</gtr:id><gtr:title>Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0d2c0dfe0782cc7d2ee3782aa782931"><gtr:id>d0d2c0dfe0782cc7d2ee3782aa782931</gtr:id><gtr:otherNames>Burrows AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DA35428-A787-4486-8486-A5251F8E434E"><gtr:id>7DA35428-A787-4486-8486-A5251F8E434E</gtr:id><gtr:title>Benchmarking of protein descriptor sets in proteochemometric modeling (part 2): modeling performance of 13 amino acid descriptor sets.</gtr:title><gtr:parentPublicationTitle>Journal of cheminformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0905c93ea1680ac62798181689f63efd"><gtr:id>0905c93ea1680ac62798181689f63efd</gtr:id><gtr:otherNames>van Westen GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1758-2946</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/085A05D5-E617-4169-A7C8-CB2C92A8B7B4"><gtr:id>085A05D5-E617-4169-A7C8-CB2C92A8B7B4</gtr:id><gtr:title>Molecular basis of fatty acid selectivity in the zDHHC family of S-acyltransferases revealed by click chemistry.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4bd270b0af5849b1fe8eb6144c246475"><gtr:id>4bd270b0af5849b1fe8eb6144c246475</gtr:id><gtr:otherNames>Greaves J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1884262-B2CD-410E-ADCC-57125DBFD676"><gtr:id>E1884262-B2CD-410E-ADCC-57125DBFD676</gtr:id><gtr:title>Microwave-assisted synthesis of 3-aminobenzo[b]thiophene scaffolds for the preparation of kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE8B940D-A4F1-4590-8C2E-694098AC8CED"><gtr:id>DE8B940D-A4F1-4590-8C2E-694098AC8CED</gtr:id><gtr:title>ChEMBL: a large-scale bioactivity database for drug discovery.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/777c0f39903ee3b7af13914feafc6e5b"><gtr:id>777c0f39903ee3b7af13914feafc6e5b</gtr:id><gtr:otherNames>Gaulton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ADEA53ED-1EF0-42F1-AA29-85A20E1C6A9A"><gtr:id>ADEA53ED-1EF0-42F1-AA29-85A20E1C6A9A</gtr:id><gtr:title>Progress in the Development of non-BET Bromodomain Chemical Probes.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ffe47534b13f851791f2c56902b9ee09"><gtr:id>ffe47534b13f851791f2c56902b9ee09</gtr:id><gtr:otherNames>Theodoulou NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58FF310B-EC5C-41E1-8256-76F52A9DDCD1"><gtr:id>58FF310B-EC5C-41E1-8256-76F52A9DDCD1</gtr:id><gtr:title>The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells</gtr:title><gtr:parentPublicationTitle>Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78f9c8812cc4cee329f399a3177bb7a8"><gtr:id>78f9c8812cc4cee329f399a3177bb7a8</gtr:id><gtr:otherNames>Librizzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A3918585-553B-4D14-ACAD-095C55D5E5F9"><gtr:id>A3918585-553B-4D14-ACAD-095C55D5E5F9</gtr:id><gtr:title>Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8d0ff914a64a0bbc58fb59f5a810f83"><gtr:id>a8d0ff914a64a0bbc58fb59f5a810f83</gtr:id><gtr:otherNames>Talapatra SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B97B43C4-034D-4F67-95BC-97B7EC90DD91"><gtr:id>B97B43C4-034D-4F67-95BC-97B7EC90DD91</gtr:id><gtr:title>Click JAHAs: conformationally restricted ferrocene-based histone deacetylase inhibitors</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/79c6810bc24c5416cc1731b11428ae57"><gtr:id>79c6810bc24c5416cc1731b11428ae57</gtr:id><gtr:otherNames>Spencer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C43C0B26-D7AC-4C19-9C04-C11EC371DC3B"><gtr:id>C43C0B26-D7AC-4C19-9C04-C11EC371DC3B</gtr:id><gtr:title>A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5db9803c29435690c225c984a30543de"><gtr:id>5db9803c29435690c225c984a30543de</gtr:id><gtr:otherNames>Diez-Ardanuy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2145CA83-630D-4D8B-96A8-20B61BA4CDAD"><gtr:id>2145CA83-630D-4D8B-96A8-20B61BA4CDAD</gtr:id><gtr:title>Thiazotropsin aggregation and its relationship to molecular recognition in the DNA minor groove.</gtr:title><gtr:parentPublicationTitle>Biophysical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52e92225234f12b3b0ac28b3134c9b2d"><gtr:id>52e92225234f12b3b0ac28b3134c9b2d</gtr:id><gtr:otherNames>Salvia MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0301-4622</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7DC5D497-FD2C-4AC9-8BE9-8849AE56F318"><gtr:id>7DC5D497-FD2C-4AC9-8BE9-8849AE56F318</gtr:id><gtr:title>Towards predictive resistance models for agrochemicals by combining chemical and protein similarity via proteochemometric modelling.</gtr:title><gtr:parentPublicationTitle>Journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0905c93ea1680ac62798181689f63efd"><gtr:id>0905c93ea1680ac62798181689f63efd</gtr:id><gtr:otherNames>van Westen GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1864-6158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB4C835C-2245-492F-8F73-D702A1E3E6B6"><gtr:id>CB4C835C-2245-492F-8F73-D702A1E3E6B6</gtr:id><gtr:title>Novel p38a MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c9121606422a6e147ff0a2accc7b365"><gtr:id>6c9121606422a6e147ff0a2accc7b365</gtr:id><gtr:otherNames>Petersen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB66F4D9-FB87-4F99-9775-87D29DF7C060"><gtr:id>AB66F4D9-FB87-4F99-9775-87D29DF7C060</gtr:id><gtr:title>Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors.</gtr:title><gtr:parentPublicationTitle>ACS medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/79c6810bc24c5416cc1731b11428ae57"><gtr:id>79c6810bc24c5416cc1731b11428ae57</gtr:id><gtr:otherNames>Spencer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1948-5875</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8EE3BC2-6C39-41B1-9EF4-A143974C3FE3"><gtr:id>B8EE3BC2-6C39-41B1-9EF4-A143974C3FE3</gtr:id><gtr:title>Clinical progress and pharmacology of small molecule bromodomain inhibitors.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ffe47534b13f851791f2c56902b9ee09"><gtr:id>ffe47534b13f851791f2c56902b9ee09</gtr:id><gtr:otherNames>Theodoulou NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC2144E9-FE83-49AF-B6DF-BFA2D0B626C6"><gtr:id>CC2144E9-FE83-49AF-B6DF-BFA2D0B626C6</gtr:id><gtr:title>Bismuth coordination networks containing deferiprone: synthesis, characterisation, stability and antibacterial activity.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0d2c0dfe0782cc7d2ee3782aa782931"><gtr:id>d0d2c0dfe0782cc7d2ee3782aa782931</gtr:id><gtr:otherNames>Burrows AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A96AE7AF-C3F3-4EDB-A817-6AD945344977"><gtr:id>A96AE7AF-C3F3-4EDB-A817-6AD945344977</gtr:id><gtr:title>Synthesis of dibenzylamino-1-methylcyclohexanol and dibenzylamino-1-trifluoromethylcyclohexanol isomers.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8b3e7f412f5248bd4ef4458c2d369d46"><gtr:id>8b3e7f412f5248bd4ef4458c2d369d46</gtr:id><gtr:otherNames>Jones DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A8C52BC6-6FD2-4ABC-B7B0-E98EDCC7C859"><gtr:id>A8C52BC6-6FD2-4ABC-B7B0-E98EDCC7C859</gtr:id><gtr:title>Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5d96315773e0efe28fd2ed8efeae36c6"><gtr:id>5d96315773e0efe28fd2ed8efeae36c6</gtr:id><gtr:otherNames>Wiejak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E63CC9AA-5524-4719-B31C-979E924793DD"><gtr:id>E63CC9AA-5524-4719-B31C-979E924793DD</gtr:id><gtr:title>Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8ebe07917c448426c03efb6546f8fd9"><gtr:id>d8ebe07917c448426c03efb6546f8fd9</gtr:id><gtr:otherNames>Gammons MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29CD6F89-07AD-468B-B48A-94FA0CC4FE21"><gtr:id>29CD6F89-07AD-468B-B48A-94FA0CC4FE21</gtr:id><gtr:title>Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells.</gtr:title><gtr:parentPublicationTitle>Pharmaceuticals (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1424-8247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77C86542-0BB5-45D0-953D-F156AB55A069"><gtr:id>77C86542-0BB5-45D0-953D-F156AB55A069</gtr:id><gtr:title>Recognition of the DNA minor groove by thiazotropsin analogues.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2e4f8ae0605e3400d2c1b3ae3d5200b5"><gtr:id>2e4f8ae0605e3400d2c1b3ae3d5200b5</gtr:id><gtr:otherNames>Alniss HY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11969B26-A0B0-4755-881E-9E2E91E2EC53"><gtr:id>11969B26-A0B0-4755-881E-9E2E91E2EC53</gtr:id><gtr:title>A public-private partnership to unlock the untargeted kinome.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94b61dccdd6b48bd6c1f8a728fd0df51"><gtr:id>94b61dccdd6b48bd6c1f8a728fd0df51</gtr:id><gtr:otherNames>Knapp S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/000B3F60-A58F-486B-94BF-E28EBF267744"><gtr:id>000B3F60-A58F-486B-94BF-E28EBF267744</gtr:id><gtr:title>Optimized chemical probes for REV-ERBa.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/feae7a04a53e4ff27655841c7c542127"><gtr:id>feae7a04a53e4ff27655841c7c542127</gtr:id><gtr:otherNames>Trump RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FC3CE4A-8025-4CF5-AB34-4F15AF067B20"><gtr:id>7FC3CE4A-8025-4CF5-AB34-4F15AF067B20</gtr:id><gtr:title>Manganese dioxide mediated one-pot synthesis of methyl 9H-pyrido[3,4-b]indole-1-carboxylate: Concise synthesis of alangiobussinine.</gtr:title><gtr:parentPublicationTitle>Beilstein journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/505ce05086e8b6527706c2e0d5225d94"><gtr:id>505ce05086e8b6527706c2e0d5225d94</gtr:id><gtr:otherNames>Baiget J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1860-5397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99041DB6-B380-4BDD-AFE3-318D8E0ABB9F"><gtr:id>99041DB6-B380-4BDD-AFE3-318D8E0ABB9F</gtr:id><gtr:title>Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d72ab0dcb9e827da71c45603704751d"><gtr:id>0d72ab0dcb9e827da71c45603704751d</gtr:id><gtr:otherNames>Good JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACFA94A5-599F-425E-B8C1-13140B25F309"><gtr:id>ACFA94A5-599F-425E-B8C1-13140B25F309</gtr:id><gtr:title>Nuclear factor ?B predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor.</gtr:title><gtr:parentPublicationTitle>Human pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc82f17f1c179e3073a986645ac03e98"><gtr:id>cc82f17f1c179e3073a986645ac03e98</gtr:id><gtr:otherNames>MacKenzie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0046-8177</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50A3E4D2-FEDA-40C0-A8B3-D127B3C8A402"><gtr:id>50A3E4D2-FEDA-40C0-A8B3-D127B3C8A402</gtr:id><gtr:title>A 8-Hydroxyquinoline-Cyclodextrin Conjugate as an Efficient Chelating Agent for Cobalt(II) and Nickel(II) in Neutral Aqueous Solution</gtr:title><gtr:parentPublicationTitle>European Journal of Inorganic Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ba92433de9670c2b999df45a9270344"><gtr:id>8ba92433de9670c2b999df45a9270344</gtr:id><gtr:otherNames>Sgarlata C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC872BC7-D6B7-4DDB-B82B-C8B6DCE2408A"><gtr:id>EC872BC7-D6B7-4DDB-B82B-C8B6DCE2408A</gtr:id><gtr:title>Oligoamides of 2-amino-5-alkylthiazole 4-carboxylic acids: anti-trypanosomal compounds</gtr:title><gtr:parentPublicationTitle>Medicinal Chemistry Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b345e541a2e9da96ad2a2614ba3ba99"><gtr:id>6b345e541a2e9da96ad2a2614ba3ba99</gtr:id><gtr:otherNames>Lang S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5C470B7-57D6-4DD3-974A-877829177683"><gtr:id>C5C470B7-57D6-4DD3-974A-877829177683</gtr:id><gtr:title>Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.</gtr:title><gtr:parentPublicationTitle>Molecular informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a36daa994b2daa4229e2c674b18d9e9d"><gtr:id>a36daa994b2daa4229e2c674b18d9e9d</gtr:id><gtr:otherNames>Walter A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1868-1743</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/993E50D8-B1DA-4D7F-9B1A-4EA95406E553"><gtr:id>993E50D8-B1DA-4D7F-9B1A-4EA95406E553</gtr:id><gtr:title>Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d]pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14e8090fe82ea95cf1df6bf07d2bba1a"><gtr:id>14e8090fe82ea95cf1df6bf07d2bba1a</gtr:id><gtr:otherNames>Bagley M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/I037229/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>